Avelumab and Merkel Cell Carcinoma: Prognosis and Treatment Insights

From General Health to Occupational Exposure Concerns

The legacy of general health and science information has long emphasized broad wellness principles and disease prevention through lifestyle modification. This foundational knowledge established public understanding of risk factors and protective behaviors across diverse populations. Within this framework, health communication traditionally focused on modifiable variables such as diet, exercise, and environmental exposures in everyday settings. The transition from this general context to more specialized occupational health considerations requires careful attention to exposure pathways that differ from common lifestyle factors. In particular, workplace environments may introduce unique chemical or biological agents that warrant distinct risk assessment approaches. One such area of emerging concern involves exposure to therapeutic monoclonal antibodies, such as avelumab, which are increasingly utilized in clinical oncology. While these agents are designed for targeted cancer treatment, their handling in manufacturing or healthcare settings raises questions about potential unintended health effects. The shift from general health education to occupational exposure concern thus necessitates a focused examination of how specific pharmaceutical compounds, when encountered in professional contexts, may influence long-term health outcomes. This pivot acknowledges that workplace exposures can present risks distinct from those addressed in conventional health guidance, requiring specialized protocols and surveillance.

Avelumab and Merkel Cell Carcinoma: A Clinical Overview

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/33439294/). This approval marked the first therapeutic agent specifically indicated for metastatic MCC, independent of line of treatment, and was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial (https://pubmed.ncbi.nlm.nih.gov/29799096/). In Part A of that study, confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), have been approved by the U.S. Food and Drug Administration for advanced MCC and offer durable responses and significant clinical benefit (https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Treatment Options and Outcomes for Avelumab-Refractory Patients

For patients who become refractory to avelumab, treatment options are limited. In Europe, approved systemic therapies for metastatic MCC are restricted to avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). For avelumab-refractory patients, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). Retrospective studies have explored the use of combined ipilimumab plus nivolumab in this setting. In one study conducted at three sites in Germany, five patients with metastatic MCC refractory to avelumab were treated with combined ipilimumab and nivolumab, and three out of five responded according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study from the prospective skin cancer registry ADOREG similarly reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study further noted that despite advances, about half of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab; the hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that irAEs can occur during treatment but may be manageable without discontinuation of therapy.

Prognosis and Risk Considerations

Regarding prognosis, MCC is a rare but highly aggressive skin cancer with neuroendocrine differentiation (https://pubmed.ncbi.nlm.nih.gov/36450381/). The prognosis for patients with metastatic MCC remains poor, though immune checkpoint inhibitors have improved outcomes (https://pubmed.ncbi.nlm.nih.gov/33439294/). The timeline between exposure to avelumab and documented harm is variable; adverse events such as immune-related reactions can occur during treatment, while the therapeutic benefit—such as objective responses—is typically assessed within weeks to months of initiating therapy, as seen in the JAVELIN Merkel 200 trial (https://pubmed.ncbi.nlm.nih.gov/29799096/). For patients who progress on avelumab, subsequent treatment with combined ipilimumab and nivolumab may offer a salvage option, though data are limited to small retrospective series (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). Adequacy of warnings regarding avelumab and MCC is addressed through the drug's prescribing information, which includes the indication for metastatic MCC and notes the risk of immune-related adverse events. However, the evidence does not specify the content of those warnings beyond the general recognition of irAEs. The risk of progression despite treatment is a key consideration, as approximately half of patients may not respond or may become refractory (https://pubmed.ncbi.nlm.nih.gov/35877101/). For affected patients, prognosis-related considerations include the potential for response to avelumab, the possibility of immune-related adverse events, and the availability of subsequent therapies such as ipilimumab plus nivolumab for those who are refractory (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is avelumab and how does it work in Merkel cell carcinoma?

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. By blocking PD-L1, avelumab helps the immune system recognize and attack cancer cells.

What is the prognosis for patients with metastatic Merkel cell carcinoma treated with avelumab?

The prognosis for metastatic MCC remains poor, but immune checkpoint inhibitors like avelumab have improved outcomes. In the JAVELIN Merkel 200 trial, about one-third of patients with chemotherapy-refractory MCC responded to avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, approximately 50% of patients may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For those who become refractory, subsequent therapies such as ipilimumab plus nivolumab may offer a salvage option (https://pubmed.ncbi.nlm.nih.gov/33439294/).

What are the common side effects of avelumab?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). These may include inflammation of organs such as the lungs, liver, colon, or skin. In some cases, irAEs can be managed with corticosteroids without discontinuing therapy. Patients should be monitored closely for any signs of immune-related reactions.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.